Hematology

University of Chicago

Questions discussed in this category

Would you consider daratumumab monotherapy as standard of care for smoldering multiple myeloma based on the AQUILA trial?

AQUILA trial - NEJM

3 Answers available

For relapsed/refractory myeloma, how long of a disease-free interval from first autologous transplant do you recommend before considering a second autologous transplant?

1 Answer available

How would one alter therapy in a transplant-ineligible AL amyloidosis with less than a complete response to six cycles of Dara-CyBorD?

Would you continue with daratumumab maintenance per ANDROMEDA or switch regimen?

2 Answers available

Papers discussed in this category

Blood Cancer J, 2021 Jan 11

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.

N Engl J Med,

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.

Lancet Haematol,

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.

Leukemia, 2020 Jul 21

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.

The New England journal of medicine, 2024 Dec 09

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.

Blood cancer journal, 2020 Oct 16

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).

Blood advances, 2023 Nov 14

CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies.

Related Topics in Hematology